Boundless Bio, Inc., biopharma company, develops therapies and medicines for the treatment of cancers. It offers therapeutics based on extrachromosomal DNA (ecDNA) one of the drivers of the aggressive cancers, such as cancers characterized by high copy number amplification of oncogenes. The company was formerly known as Pretzel Therapeutics, Inc. Boundless Bio, Inc. was founded in 2018 and is based in LA Jolla, California.
AMP Robotics Corporation specializes in designing and manufacturing robotic systems for material recovery facilities and recycling operations, focusing on automating the identification, sorting, and processing of complex waste streams. The company's flagship product, AMP Cortex, utilizes advanced robotics and computer vision technology to efficiently pick and sort recyclable materials, significantly lowering sorting costs. Additionally, AMP Neuron, a software solution, captures and analyzes material data to identify features in a manner similar to human perception. By leveraging artificial intelligence and machine learning, AMP Robotics enhances recycling processes for various waste types, including municipal solid waste and e-waste. The modular design of its systems allows for easy integration into existing infrastructure, minimizing disruption and capital investment. Founded in 2014 and headquartered in Louisville, Colorado, AMP Robotics has formed strategic partnerships to further its mission of improving recycling rates and economic recovery of recyclables.
Meati, also known as Emergy Foods, is a consumer goods company based in Boulder, Colorado, founded in 2016. The company specializes in producing whole muscle, nutritious plant-based meats designed to promote healthier lifestyles and environmental sustainability. By utilizing proprietary, clean technologies, Meati offers nutrient-dense meat alternatives that aim to appeal to a wide audience, ensuring that consumers can enjoy meals that are both good for their health and the planet.
Learneo brands and platforms are pioneering advances in a wide range of applications for emergent technologies, including the use of AI to improve people's writing, reading and math skills, in school, professional and daily life. The platform of businesses includes CliffsNotes, the original and iconic study guide company; Course Hero, an online learning platform of academic resources; LitCharts, a creator of literature resources; QuillBot, an AI-powered writing companion helping anyone improve their writing skills; Scribbr, a multilingual academic proofreading service, and Symbolab, an AI-based mathematics resource. Learneo was established in Redwood City, California by Andrew Grauer and Gregor Carrigan.
Strata Oncology is a precision oncology company dedicated to transforming cancer care by expanding patient access to precision medicine clinical trials and accelerating drug approval.
Strata's national precision oncology platform serves the needs of patients, providers and drug developers by providing a link from patient screening to streamlined enrollment in mutation-matched clinical trials. Follow us on Twitter @StrataOncology.
Sundae operates a home-selling platform designed to assist homeowners in selling houses that are outdated or in need of repairs. The company addresses the challenges faced by sellers in a traditional real estate market, where local investors often exploit homeowner distress to acquire properties at low prices. Sundae aims to provide a better outcome for these sellers by offering competitive off-market prices without the need for cleanup, repairs, or showings. Through a data-driven model, Sundae anticipates when homeowners may require assistance and employs a skilled sales and marketing team to effectively reach them. By prioritizing the needs of sellers and redistributing economic value, Sundae strives to become a leading buyer of homes that require significant attention across the United States.
Lendbuzz Funding, LLC offers car loans to expats and international students. The company does not require Social Security Number (SSN) and provides loans to all visa holders from all nationalities. Its customers include students, international professionals, and other young professionals that have an international credit file. The company provides access and manages its loans through an online platform and data-intensive scoring technology. Lendbuzz Funding, LLC was founded in 2015 and is based in Boston, Massachusetts.
NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and located in Wilmington, Delaware. The company is dedicated to discovering and developing innovative small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. By employing a discovery approach that leverages target structure biology and structure-based drug design, NiKang Therapeutics aims to facilitate the rapid and efficient development of proprietary drug candidates with optimal pharmacological properties. The company seeks to enhance the treatment options available to healthcare providers, ultimately improving patient outcomes in the fight against cancer.
Cityblock Health is a healthcare provider focused on delivering primary care, behavioral health, and virtual care services to lower-income communities. Established in 2017 and based in Brooklyn, New York, Cityblock leverages technology to offer personalized, prevention-oriented care for urban residents with complex health needs. The company's platform facilitates access to preventive visits, mental health services, and social support programs. Additionally, Cityblock offers a communication tool called Commons, which enhances information sharing and task management among members and care teams. During the COVID-19 pandemic, Cityblock developed a model to identify individuals at high risk, highlighting its commitment to addressing urgent health challenges. By prioritizing upstream investments in health and social care, Cityblock aims to improve health outcomes while reducing overall costs.
Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, that specializes in developing vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins in a single vaccine, aiming to enhance the immune response against various infectious diseases. Affinivax focuses on a range of pathogens, including Streptococcus pneumoniae, which poses significant health risks to both children and adults. The company seeks to create vaccines that provide broader disease coverage and address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from insights provided by leading experts in infectious diseases and vaccines, and it has secured support from the Bill & Melinda Gates Foundation, along with exclusive licensing rights from Boston Children’s Hospital for its MAPS technology.
Cityblock Health is a healthcare provider focused on delivering primary care, behavioral health, and virtual care services to lower-income communities. Established in 2017 and based in Brooklyn, New York, Cityblock leverages technology to offer personalized, prevention-oriented care for urban residents with complex health needs. The company's platform facilitates access to preventive visits, mental health services, and social support programs. Additionally, Cityblock offers a communication tool called Commons, which enhances information sharing and task management among members and care teams. During the COVID-19 pandemic, Cityblock developed a model to identify individuals at high risk, highlighting its commitment to addressing urgent health challenges. By prioritizing upstream investments in health and social care, Cityblock aims to improve health outcomes while reducing overall costs.
Edgewise Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, specializing in the development of small molecule therapies for severe musculoskeletal diseases. Founded in 2017, the company leverages its expertise in skeletal muscle physiology to create innovative treatments for genetically defined muscle disorders, including Duchenne, Becker, and limb girdle muscular dystrophies. Edgewise Therapeutics employs a precision medicine platform to identify and target key muscle proteins and modulators, aiming to address the underlying causes of these conditions. Additionally, the company has established a state-of-the-art research facility to enhance its capabilities in understanding muscle adaptation and injury related to disease.
Current is a leading U.S. challenger bank built to meet the needs of people with unique lives who have been overlooked by the traditional banking industry. Our proprietary Current Core technology allows us to provide premium banking services for everyone, regardless of age or income, and improve the financial outcomes of our members without overdraft fees, minimum balance requirements, or hidden fees. We give members up to two days faster direct deposit paychecks, free overdrafts up to $100 with Overdrive™ , points on purchases redeemable for cash back, access to 55,000 free ATMs worldwide as well as 24/7 member support 365 days a year.
Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering and developing innovative cell therapies for cancer treatment. The company's lead product candidates include GC012F, a dual-targeted CAR-T therapy for multiple myeloma currently in Phase I trials; GC019F, which targets adult B cell acute lymphoblastic leukemia and is also in Phase I trials; and GC007F, aimed at B cell non-Hodgkin’s lymphoma, also in Phase I. Additionally, Gracell is developing GC027, a CAR-T candidate targeting adult T cell acute lymphoblastic leukemia, and GC007g, an allogeneic CAR-T therapy for relapsed or refractory B-ALL, both in Phase I trials. Beyond these, Gracell has a pipeline of earlier-stage product candidates targeting various cancers, including ovarian and breast cancer. Founded in 2017, Gracell Biotechnologies is committed to advancing cellular therapeutics to improve patient outcomes in hematological malignancies and solid tumors.
Olema Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapies for women's cancers, particularly focusing on estrogen receptor-positive breast cancer. The company's lead candidate, OP-1250, is an estrogen receptor antagonist and selective degrader, currently undergoing Phase 1/2 clinical trials for the treatment of metastatic or locally advanced, estrogen receptor-positive, and human epidermal growth factor receptor 2-negative breast cancer. Olema Oncology aims to innovate targeted therapies by leveraging its expertise in endocrine-driven cancers and mechanisms of acquired resistance. The company seeks to enhance treatment options for both pre- and post-menopausal women with breast cancer, striving to transform the standard of care with more effective and convenient therapies. Founded in 2006 and headquartered in San Francisco, California, Olema was previously known as CombiThera, Inc. and rebranded in 2009.
Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.
NovellusDx, Ltd. is a biotechnology company based in Jerusalem, Israel, established in 2011 by Haim Gil-ad and Yoram Altschuler. The company specializes in developing targeted therapies for cancer patients by focusing on tumor-specific driver mutations. NovellusDx utilizes innovative testing methods to evaluate the effectiveness of targeted therapy drugs on emulated tumors, allowing for the quantification of therapeutic effects. The company also monitors the oncogenic activity of relevant genes and proteins in patients, assessing changes before and after drug administration. Additionally, NovellusDx develops assays to detect the misregulated translocation of mutated signaling proteins to the nucleus, measuring the impact of drug candidates on specific tumors, particularly concerning their ability to inhibit the translocation of up-regulated signaling proteins.
Freeline Therapeutics is a clinical-stage biotechnology company focused on developing liver-directed gene therapies for bleeding disorders and other diseases. Based in Stevenage, United Kingdom, Freeline's lead product candidate, FLT180a, is undergoing Phase 1/2 clinical trials aimed at treating moderate to severe hemophilia B. The company's pipeline also includes FLT190, which is in dose-escalating Phase 1/2 trials for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A. Freeline utilizes a next-generation proprietary adeno-associated virus (AAV) vector platform, enhancing its potential for systemic gene therapy applications. Since its founding in 2015, the company has been dedicated to advancing innovative treatments in the field of gene therapy.
Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, established in 2015. It specializes in targeted protein degradation, developing innovative small molecule therapeutics that selectively degrade proteins associated with various diseases by utilizing the body's natural protein degradation mechanisms. The company is advancing several therapeutic programs, including the IRAK4 program aimed at treating immunology-inflammation diseases such as hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis. Additionally, it is developing the IRAKIMiD program for MYD88-mutated diffuse large B cell lymphoma and the STAT3 program for hematologic malignancies and solid tumors, as well as autoimmune diseases. Through its proprietary predictive modeling platform, Kymera Therapeutics seeks to accelerate drug discovery and address previously untreatable conditions.
Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing gene therapies aimed at treating both rare and prevalent diseases. Established in 2016, the company focuses on conditions affecting the liver, retina, skeletal muscle, central nervous system, and oncology. Generation Bio employs an innovative non-viral platform that includes a proprietary high-capacity DNA construct known as closed-ended DNA (ceDNA), a cell-targeted lipid nanoparticle delivery system (ctLNP), and a scalable, capsid-free manufacturing process. This approach allows for the targeted delivery of genetic materials, including large and multiple genes across various tissues, and enables redosable treatments tailored to individual patient needs. By enhancing access to therapies for rare diseases and addressing more common conditions, Generation Bio aims to provide durable and sustainable treatment options for patients throughout their lives.
Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule, tumor-agnostic therapies. The company's lead product candidate, BDTX-189, is designed to inhibit specific mutations in ErbB kinases, including the epidermal growth factor receptor. Additionally, Black Diamond is advancing a pipeline of allosteric-EGFR mutation inhibitors and other early-stage programs targeting allosteric mutations in kinases associated with cancer and rare genetic diseases. The company employs a technology platform known as Mutation-Allostery-Pharmacology, which aims to address undrugged mutations in patients with genetically defined cancers. Founded in 2014 and based in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its rebranding in 2018.
Atreca, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on discovering and developing antibody-based immunotherapeutics for various solid tumors. Its lead product candidate, ATRC-101, is a monoclonal antibody currently in clinical development, which demonstrates a unique mechanism of action and targets derived from antibodies identified through Atreca's innovative discovery platform. ATRC-101 has shown in vitro reactivity with a significant majority of cancer samples, including those from ovarian, non-small cell lung, colorectal, and breast cancer patients. Additionally, the company has established a strategic research collaboration with Merck Sharp & Dohme Corp. to identify antigenic targets of select antibodies with potential applications in oncology. Founded in 2010, Atreca aims to advance its therapies to improve treatment options for cancer patients.
Arcus Biosciences is biotech company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. Arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the San Francisco bay area, in the heart of the world’s largest biotechnology research hub.
Nightstar Therapeutics plc is a clinical-stage gene therapy company based in London, focused on developing innovative one-time treatments for rare inherited retinal diseases. The company’s lead product candidate, NSR-REP1, is currently in phase 3 clinical development for choroideremia, while NSR-RPGR is undergoing phase 2/3 trials for X-linked retinitis pigmentosa. Additionally, Nightstar is developing NSR-BEST1 and NSR-ABCA4, with the latter in preclinical development for Stargardt disease. Founded in 2017, Nightstar Therapeutics aims to address the unmet medical needs of patients suffering from these conditions.
Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications.
It was founded in 2005 and headquartered in Cambridge, Massachusetts.
The Trade Desk is a technology company that operates a self-service cloud-based platform designed for buyers of digital advertising. Established in 2009 and headquartered in Ventura, California, it enables advertising agencies and other service providers to create, manage, and optimize data-driven campaigns across various formats, including display, video, audio, native, and social media. The platform supports multiple devices, such as computers, mobile devices, and connected TVs. By leveraging data, The Trade Desk helps advertisers programmatically find and purchase digital ad inventory while optimizing the performance of their campaigns. The company's revenue model is primarily based on fees, which are calculated as a percentage of the advertising spend by its clients. With a global presence, The Trade Desk serves clients in the United States, Europe, and Asia, providing essential tools for digital media buyers.
Magic Leap is a US-based company focused on developing wearable augmented reality technology that enhances user interaction with digital devices. The company is innovating in the augmented reality sector, creating hardware and software designed to provide a unique AR experience that transforms how users access screens and visualize data. Their headset integrates users' natural visual capabilities with mobile computing, producing visual outputs that closely resemble real-world experiences. Utilizing a Dynamic Digitized Lightfield Signal, Magic Leap generates images that are indistinguishable from actual objects, allowing for seamless integration of digital content into the physical environment. The company's platform aims to improve productivity, particularly in enterprise settings, by enabling users to engage with both digital and real-world elements in an immersive manner.
Allena Pharmaceuticals is developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrology and urologic conditions. Its proprietary technological approach enables the design, formulation, and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract.
It was founded in 2011 and headquartered in Newton, Massachusetts.
Rubicon Global Holdings LLC is a technology company that specializes in cloud-based waste and recycling solutions for businesses, governments, and nonprofits. Founded in 2008 and headquartered in Atlanta, Georgia, Rubicon operates a digital marketplace and offers a suite of software-as-a-service products aimed at enhancing waste management and recycling efforts. The company provides various recycling programs, including services for cardboard, plastic, paper, metal, glass, electronics, and organics, as well as single stream recycling solutions. One of its notable offerings is RUBICONSmartCity, which assists municipal governments in optimizing waste and recycling operations while transforming their fleets into data collection centers to improve quality of life and government services through data analytics. Rubicon serves a global customer base and maintains core teams in several U.S. cities, including New York and San Francisco. The company is committed to driving environmental innovation and helping its partners achieve sustainability goals by finding economic value in waste streams.
TabbedOut puts you in control of your tab at bars and restaurants. Say goodbye to end-of-night bar lines, and flagging down your server when you’re ready to settle the bill. Never leave your card at the bar again! TabbedOut is easier and more secure than handing over your credit card to a stranger. Open a tab, view the running total, and pay for it instantly (and securely) all from your phone. You can even split your tab among friends, post to Facebook or Twitter to let your friends know where you’re dining, send a positive or negative review of your experience, and get offers sent from your favorite venue straight to your phone. TabbedOut takes the hassle out of dining out for good. We are adding new locations every day, so check in often on the locations screen. Don’t see your favorite bar or restaurant on the list? Let us know! Tweet at or Facebook us at @tabbedout. For merchants: TabbedOut is the premier marketing and analytics platform built exclusively for the hospitality industry and powered by mobile payments. We allow our merchants real time insight into their customers through our proprietary software system that tracks spending habits, product preferences, customer feedback and loyalty rewards. Best of all, TabbedOut allows you, the merchant, to accept mobile payments integrated into your POS system. Finally, POS systems and mobile payments meet customer marketing and rewards in real time. That’s the power of TabbedOut! Free to download and no hidden fees.
Harry's, Inc. is a company that specializes in the manufacture and sale of shaving products. Founded in 2012 and headquartered in New York, the company designs and produces its own line of razors, replacement blades, shaving creams, grooming kits, and face care products. Harry's operates primarily through an online platform, offering its products individually or through a subscription model, catering to men's grooming needs. By focusing on quality and convenience, Harry's aims to simplify the shaving experience for consumers.
Oscar Health is a health insurance company that provides individual and family plans, Medicare Advantage, and small group products. Founded in 2012 and headquartered in New York, Oscar Health operates in several states, including New York, Texas, California, New Jersey, Ohio, and Tennessee. The company aims to enhance the healthcare experience by utilizing technology, design, and data to create user-friendly services. Its platform includes a software application that helps users find doctors based on location and ratings. Oscar Health primarily serves individuals and families who do not receive health insurance from their employers.
Blueprint Medicines Corporation focuses on developing small molecule kinase inhibitors aimed at treating genomic drivers in cancers, rare diseases, and enhancing cancer immunotherapy. The company is advancing several key drug candidates, including avapritinib for systemic mastocytosis and gastrointestinal stromal tumors, BLU-263 for indolent systemic mastocytosis and other mast cell disorders, and fisogatinib for advanced hepatocellular carcinoma, currently in Phase I clinical trials. Additionally, pralsetinib targets RET-altered non-small cell lung cancer and other solid tumors, while BLU-782 is being investigated for fibrodysplasia ossificans progressive. Founded in 2008 and headquartered in Cambridge, Massachusetts, Blueprint Medicines emphasizes the development of personalized cancer therapies by leveraging insights into cancer genomics and utilizing a proprietary chemical library to identify new therapeutic compounds. The company collaborates with various partners, including Clementia Pharmaceuticals and Genentech, to enhance its research and development efforts.
The Honest Company is a consumer products company founded in 2011 and headquartered in Santa Monica, California. It specializes in eco-friendly and affordable products for families, focusing on three primary categories: Diapers and Wipes, Skin and Personal Care, and Household and Wellness. The company offers a variety of products, including eco-friendly diapers, bath and skincare items, household cleaners, and organic nutritional supplements, which can be customized and bundled for convenient delivery. Its business model includes both retail and digital channels, ensuring that products are accessible to consumers wherever they shop. The majority of the company's revenue is generated from the sale of diapers and wipes, reflecting its commitment to providing safe, effective, and environmentally conscious products for everyday use.
Civitas Therapeutics is a biopharmaceutical company dedicated to developing therapies for pulmonary delivery. The company focuses on creating innovative treatments for central nervous system and respiratory disorders, with a particular emphasis on conditions such as multiple sclerosis and spinal cord injuries. Civitas Therapeutics aims to improve the health and quality of life for patients across the United States through its specialized drug delivery systems.
Datalogix® is the industry-recognized leader at connecting digital media and offline purchasing data. We help more than half of the top 100 consumer marketers increase the effectiveness and measurability of their advertising. DLX Platform®, encompasses over $1 trillion in consumer spending and powers campaigns for more than 75% of online media companies. DLX ROI® is rapidly becoming the industry standard for measuring offline sales lift for digital media. Datalogix also offers predictive analytics for Direct Mail, and integrated media solutions via the DLX Net. Our expertise spans the major consumer segments, including Retail, CPG, Automotive, Telecom, Travel and Financial Services. We are based in Colorado, with offices in New York City, San Francisco, Boston, Chicago, Detroit, and London.
Malauzai was incorporated in 2009 in response to the growing demand for a technology company that could provide innovative mobile solutions for community financial organizations. As a cool company in a cool town with a focus primarily on community financial institutions, Malauzai provides Consumer, Small Business, Employee SmartApps, SmartwebApps and SmartwearApps that enhance the customer experience for mobile and Internet banking, ultimately resulting in increased value for financial institutions.
SensAble Technologies, Inc. offers force-feedback haptic devices and touch-enabled 3D modeling software solutions. Its products include FreeForm Modeling Systems, which are 3D touch-enabled systems for medical and dental modeling, product design, digital content creation, and fine arts; and The SensAble Dental Lab System, a digital system for scanning, 3D modeling and design, and 3D fabrication. The company also provides PHANTOM Haptic Devices, which deliver force feedback, 3D navigation, and virtual workspaces; and OpenHaptics, a software development toolkit for developing haptic applications. In addition, it offers 3D touch-enabled modeling systems, software and devices, and 3D modeling software, and sculptural modeling for digital content creation and fine arts. SensAble Technologies serves academic/education, automotive/motorcycle, ceramics, characters and creatures, collectibles/giftware, confectionary, consumer products, dental, engraving, relief and flatware, facial reconstruction, film and video, fine arts and sculpture, footwear, games, home decor and housewares, jewelry, medical, packaging, personal care products, sporting goods, tooling, toys and promotional, assembly path planning, molecular modeling, simulation and visualization, and training industries. The company's products are used in product design, medical and dental modeling, digital content creation, fine arts applications, surgical simulation and stroke rehabilitation, dental restorations, and research and robotic applications. It offers its products through inside sales channels and resellers. The company was founded as SensAble Devices, Inc. in 1993 and changed its name to SensAble Technologies, Inc. in 1996. SensAble Technologies, Inc. is based in Woburn, Massachusetts with a sales office in Tokyo, Japan.